[HTML][HTML] Clinical application of radiolabeled RGD peptides for PET imaging of integrin αvβ3
Molecular imaging for non-invasive assessment of angiogenesisis is of great interest for
clinicians because of the wide-spread application of anti-angiogenic cancer therapeutics …
clinicians because of the wide-spread application of anti-angiogenic cancer therapeutics …
Nanotheranostics for personalized medicine
Nanotheranostics, the integration of diagnostic and therapeutic function in one system using
the benefits of nanotechnology, is extremely attractive for personalized medicine. Because …
the benefits of nanotechnology, is extremely attractive for personalized medicine. Because …
First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination
W Wan, N Guo, D Pan, C Yu, Y Weng… - Journal of Nuclear …, 2013 - Soc Nuclear Med
18F-FPPRGD2, which was approved for clinical study recently, has favorable properties for
integrin targeting and showed potential for antiangiogenic therapy and early response …
integrin targeting and showed potential for antiangiogenic therapy and early response …
68Ga-PSMA-11 dynamic PET/CT imaging in primary prostate cancer
C Sachpekidis, K Kopka, M Eder… - Clinical nuclear …, 2016 - journals.lww.com
Purpose The aim of our study is to assess the pharmacokinetics and biodistribution of 68 Ga-
PSMA-11 in patients suffering from primary prostate cancer (PC) by means of dynamic and …
PSMA-11 in patients suffering from primary prostate cancer (PC) by means of dynamic and …
PET radiopharmaceuticals for imaging integrin expression: tracers in clinical studies and recent developments
R Haubner, S Maschauer… - BioMed research …, 2014 - Wiley Online Library
Noninvasive determination of integrin expression has become an interesting approach in
nuclear medicine. Since the discovery of the first 18F‐labeled cyclic RGD peptide as …
nuclear medicine. Since the discovery of the first 18F‐labeled cyclic RGD peptide as …
68Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer
Objectives We aim to investigate the pharmacokinetics and distribution of the recently
clinically introduced radioligand 68 Ga-PSMA-11 in men with recurrent prostate cancer (PC) …
clinically introduced radioligand 68 Ga-PSMA-11 in men with recurrent prostate cancer (PC) …
18 F-Alfatide II PET/CT in healthy human volunteers and patients with brain metastases
C Yu, D Pan, B Mi, Y Xu, L Lang, G Niu, M Yang… - European journal of …, 2015 - Springer
Purpose We report the biodistribution and radiation dosimetry of an integrin α v β 3 specific
PET tracer 18 F-AlF-NOTA-E [PEG 4-c (RGDfk)] 2)(denoted as 18 F-Alfatide II). We also …
PET tracer 18 F-AlF-NOTA-E [PEG 4-c (RGDfk)] 2)(denoted as 18 F-Alfatide II). We also …
68Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer
Purpose The aims of this retrospective analysis were to compare 68 Ga-PSMA PET findings
and low-dose CT findings (120 kV, 30 mA), and to obtain semiquantitative and quantitative …
and low-dose CT findings (120 kV, 30 mA), and to obtain semiquantitative and quantitative …
[HTML][HTML] Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours
ADAPTs are small engineered non-immunoglobulin scaffold proteins, which have
demonstrated very promising features as vectors for radionuclide tumour targeting …
demonstrated very promising features as vectors for radionuclide tumour targeting …
Quantitative Analysis and Comparison Study of [18F]AlF-NOTA-PRGD2, [18F]FPPRGD2 and [68Ga]Ga-NOTA-PRGD2 Using a Reference Tissue Model
With favorable pharmacokinetics and binding affinity for αvβ3 integrin, 18F-labeled dimeric
cyclic RGD peptide ([18F] FPPRGD2) has been intensively used as a PET imaging probe for …
cyclic RGD peptide ([18F] FPPRGD2) has been intensively used as a PET imaging probe for …